Keywords: |
bone neoplasms; review; dose response; nonhuman; bone metastasis; combined modality therapy; prostate specific antigen; phase 2 clinical trial; bone marrow suppression; radiotherapy; tumor markers, biological; cancer hormone therapy; prostate cancer; prostate-specific antigen; prostatic neoplasms; gastrointestinal toxicity; immunotherapy; antigens, neoplasm; phase 1 clinical trial; radioisotope; suramin; intravenous drug administration; samarium 153; rhenium 186; prognosis; human; male; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; polyradiculitis
|